QuidelOrtho
In Brief This Week: QuidelOrtho, Revvity, CeGaT, Mindera Health, Fluxergy, NeuroKaire, More
News items for the week of Nov. 18, 2024.
Top Five Articles on 360Dx Last Week: Changes at QuidelOrtho; Diasorin Seeks FDA Clearance; More
Last week, readers were most interested in a story about QuidelOrtho's ongoing restructuring to support profitability.
In the wake of suspending guidance to review the business in the first quarter of the year, QuidelOrtho has restructured and resumed offering a financial outlook.
360Dx Top 30 Falls 3 Percent in October
Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.
POC High-Sensitivity Troponin Tests Could Reduce ER Overcrowding. Is That Enough for Adoption?
Premium
Several firms are bringing high-sensitivity cardiac troponin testing into the ER, although doctors are not yet certain how much difference the tests will make.
Sep 5, 2024
Craig-Hallum Upgrades QuidelOrtho to Buy
Aug 29, 2024
QuidelOrtho Nabs FDA 510(k) for Syphilis Assay
Jul 1, 2024
360Dx Top 30 Slides 2 Percent in June
Mar 6, 2024
Mar 4, 2024
UBS Downgrades QuidelOrtho to Sell
Mar 1, 2024